Drug discovery is becoming faster, more precise, and increasingly integrated, with advances in high-throughput screening, protein science, disease modeling, and AI-driven antibody development helping researchers move promising targets toward therapeutic development.
In this New horizons in drug discovery: High-throughput & target-to-therapy advances eBook, sponsored by Sino Biological US, we explore the technologies and approaches supporting drug discovery from early target identification and assay development through to biotherapeutic optimization and translational research.
Download the eBook
What’s inside the eBook?
This edition begins by examining how cell-free expression and surface plasmon resonance can support AI-driven drug discovery, before exploring high-throughput kinase assays designed to improve sensitivity and screening efficiency. It also considers the importance of international collaboration in advancing next-generation bioprocessing and how the Fc region can influence the clinical performance of biotherapeutics.
The collection then looks at human-based organoid solutions for more representative disease modeling and explores the growing importance of Tau in the diagnosis and treatment of Alzheimer’s disease. Finally, it examines how high-throughput antibody expression and validation are accelerating the transition from AI-generated predictions to functional antibodies, and how greater precision in targeting cell-surface proteins can open new opportunities for therapeutic research.
Whether you work in drug discovery, assay development, bioprocessing, antibody development, or therapeutic development, this eBook provides insight into the tools and strategies helping bridge the gap between biological targets and new therapies.
Highlights from this eBook include:
- From AI prediction to antibody validation in days
-
Boost assay sensitivity and throughput with SwiftFluo TR-FRET kinase kits
-
5 ways international collaboration is accelerating next-gen bioprocessing
-
How the Fc region shapes the clinical success of your biotherapeutic
-
Enabling organoid innovation with comprehensive human-based solutions
-
How Tau is transforming the future of Alzheimer’s diagnosis and treatment
- Streamlining AI-driven drug discovery with cell-free expression and SPR
-
Targeting cell-surface proteins with greater precision
Download the eBook
About Sino Biological Inc.
Founded in 2007, Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and CRO services. Serving researchers in over 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.
Sino Biological's core business
Sino Biological is a leading global biotechnology supplier dedicated to high-quality research reagents and comprehensive CRO services. Its extensive product portfolio covers over 9,800 recombinant proteins, 15,000 antibodies, and 50,000 genes, all produced in-house. As a trusted CRO partner, Sino Biological specializes in customized recombinant protein and antibody production. It stands out with its robust high-throughput antibody production system, including HEK293/CHO and cell‑free platforms. This system enables rapid turnaround (as fast as 5 days), high-throughput production (> 10,000 Abs/month), and cost-effective solutions for global academic and pharmaceutical clients.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.